Fnac in non palpable lesion of breast md pathology 10 marks answer
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Searching the Web
FNAC non palpable breast lesion pathology procedure cytological reporting categories MD exam
I now have comprehensive material to write a thorough 10-mark MD Pathology answer. Here is the complete structured answer:
FNAC in Non-Palpable Lesions of the Breast
Introduction
Fine Needle Aspiration Cytology (FNAC) is a minimally invasive, outpatient procedure for sampling breast tissue using a thin needle with suction. When a lesion is non-palpable (occult on clinical examination but detected by screening mammography, ultrasound, or MRI), FNAC cannot be performed by blind palpation and requires image guidance to accurately target the lesion. Non-palpable lesions include mammographically detected microcalcifications, architectural distortion, asymmetric densities, and small sonographic masses.
Why Image Guidance is Mandatory
Non-palpable lesions are invisible to clinical touch. Without guidance:
- False-negative rates are unacceptably high (inadequacy rates as high as 34-58% have been reported for non-palpable lesions)
- Sampling errors are frequent due to small lesion size and fibrotic stroma
- In one study, 21% of false-negative breast FNACs were attributable to non-palpable tumors
Image guidance dramatically reduces sampling error, improves adequacy, and enables real-time needle placement confirmation.
Methods of Image-Guided FNAC
1. Ultrasound-Guided FNAC
- Preferred method for non-palpable solid masses visible on sonography
- Provides real-time visualization of the needle tip within the lesion
- Allows biopsy from multiple angles, including posterior lesions
- Technique: Target centered in field of view; depth adjusted to visualize chest wall; local anesthetic injected; 22-25 gauge needle advanced into the target under direct visualization; multiple short passes made to collect cells within the cannula
2. Stereotactic (Mammography-Guided) FNAC
- Used for lesions visible only on mammography - particularly microcalcifications and architectural distortion without a sonographic correlate
- Two paired oblique images (typically at -15 and +15 degrees) are obtained; the computer calculates lesion depth from the parallax shift
- The needle is advanced to pre-fire position; confirmatory paired images are taken; the device fires and samples are collected
- A specimen radiograph is obtained post-biopsy to confirm adequate sampling of calcifications
- A metallic clip is placed at the biopsy site for future localization
3. MRI-Guided FNAC
- Reserved for lesions seen only on MRI (non-mass enhancement not visible on mammography or ultrasound)
- Technically demanding; requires MRI-compatible needles and a dedicated breast coil
Technical Procedure of FNAC
- Patient positioned appropriately; skin prepared with antiseptic
- Local anesthesia (e.g., 1% lignocaine) infiltrated
- A small skin nick made with a scalpel
- A 22-25 gauge needle attached to a 10 mL syringe is advanced to the lesion under image guidance
- Suction applied; multiple short passes (to-and-fro movements) made within the lesion
- Once cellular material appears at the hub, suction is released before withdrawing the needle
- Material expressed onto glass slides; both air-dried (for Giemsa/MGG stain) and 95% ethanol-fixed (for Papanicolaou stain) smears are prepared
- A cytopathologist may perform rapid on-site evaluation (ROSE) to assess specimen adequacy before the patient leaves
- A metallic marker clip is placed at the biopsy site; post-procedure mammogram confirms clip placement
Cytological Reporting - The Five-Tier (C) System
The most widely used reporting system for breast FNAC is the five-category (C1-C5) scheme, also aligned with the IAC Yokohama System:
| Category | Designation | Description | Risk of Malignancy | Management |
|---|---|---|---|---|
| C1 | Inadequate/Insufficient | Hypocellular or poorly preserved; fewer than 6 well-visualized epithelial cell groups | - | Repeat FNAC or core biopsy |
| C2 | Benign | Adequate cellularity; benign features (e.g., fibroadenoma, fibrocystic change, cyst contents, lactational change) | Very low | Imaging follow-up |
| C3 | Atypical / Uncertain | Some atypia but insufficient for malignancy; overlapping features with low-grade DCIS or atypical hyperplasia | Intermediate | Core needle biopsy recommended |
| C4 | Suspicious of Malignancy | Strong features of malignancy but insufficient for definitive diagnosis | High | Core biopsy / excision mandatory |
| C5 | Malignant | Unequivocal cytologic features of malignancy | >99% PPV | Definitive surgical / oncological management |
The Triple Test
FNAC of breast lesions (palpable or non-palpable) is best interpreted as part of the Triple Test:
- Clinical/Imaging findings (mammography, ultrasound, MRI - BIRADS category)
- Cytological result (C1-C5)
- Histopathology (core needle biopsy if needed)
When all three components are concordantly negative or positive, the positive predictive value approaches 100%. If any component is discordant, core needle biopsy or excision is mandatory before clinical treatment.
Advantages of FNAC
- Minimally invasive, well tolerated under local anesthesia
- Low complication rate (hematoma, infection rare)
- Rapid result (same-day with ROSE)
- Inexpensive compared to core biopsy or open biopsy
- Can be performed in outpatient setting
Limitations of FNAC in Non-Palpable Lesions
- Cannot distinguish in situ from invasive carcinoma - cells lose their architectural orientation
- Inadequacy rate is higher for non-palpable lesions (10-58%) vs. palpable masses, due to small size and fibrosis
- Cannot provide receptor status (ER, PR, HER2) reliably from cytology alone (core biopsy preferred for this)
- Lobular carcinoma is a specific diagnostic pitfall - subtle cytologic atypia and cell resemblance to lymphocytes cause false negatives
- Low-grade tumors and special-type carcinomas are frequent false-negatives (~24-39% of false negatives)
FNAC vs. Core Needle Biopsy for Non-Palpable Lesions
| Feature | FNAC | Core Needle Biopsy (CNB) |
|---|---|---|
| Gauge | 22-25 G | 8-14 G |
| Architecture preserved | No | Yes |
| In situ vs. invasive | Cannot distinguish | Can distinguish |
| Receptor status | Limited | Reliable |
| Adequacy for non-palpable | Lower | Higher (>95%) |
| Cost | Lower | Higher |
| Complication rate | Very low | Low |
For non-palpable lesions today, core needle biopsy is preferred over FNAC in most centers because it preserves architecture, allows assessment of invasion status, permits receptor marker analysis by immunohistochemistry, and has a lower inadequacy rate. FNAC retains a role for cystic lesions, lymph nodes, and likely-benign lesions, and in centers with cytopathology expertise and rapid on-site evaluation.
Conclusion
FNAC of non-palpable breast lesions requires mandatory image guidance (ultrasound, stereotactic, or MRI), meticulous smear preparation, and reporting using the standardized five-tier C1-C5 system. Its diagnostic accuracy is maximized within the triple test framework. Despite increasing use of core needle biopsy for non-palpable lesions, FNAC remains a valuable, rapid, and cost-effective first-line tool - particularly in resource-limited settings and for specific lesion types - provided operator skill and cytopathology expertise are available.
References:
- Schwartz's Principles of Surgery, 11th Ed. - Breast Biopsy, Non-palpable Lesions
- Fischer's Mastery of Surgery, 8th Ed. - Image-Guided Breast Procedures
- IAC Yokohama System for Reporting Breast Cytopathology (Yokohama 5-tier framework)
- FNAC of Breast: The Nonmalignant Categories - PMC review on non-palpable lesion challenges and false-negative factors
This is a shared conversation. Sign in to Orris to start your own chat.